Forbes July 23, 2024
When drugmaker Gilead Sciences announced interim late-stage trial results of its injectable HIV prevention drug last month, researchers, advocates and Wall Street collectively rejoiced. None of the more than 2,000 women at high risk for contracting HIV who were given two annual injections of lenacapavir were infected. “It is gobsmackingly exciting to see zero in a clinical trial,” Mitchell Warren, executive director of the global HIV prevention nonprofit AVAC told Forbes.
The results were so promising that an independent committee recommended all of the 5,300 women participating in the trial get the twice-yearly injections rather than continuing with comparison groups taking daily oral pills, which averaged around two out of every 100 women getting infected. As the 25th annual International...
Today's Sponsors
Today's Sponsor